-
ASAM Comments on Special Registrations for Telemedicine Proposed Rule
Full story -
AKSAM Supports Legislation to Bolster Youth Tobacco Prevention
Full story -
Guest Editorial – Advancing Reduction of Drug Use as an Endpoint in Addiction Treatment Trials
For many people trying to recover from a substance use disorder, perhaps for the majority, abstinence may be the most appropriate treatment objective. But complete abstinence is sometimes not achievable, even in the long-term, and there is a need for new treatment approaches that recognize the clinical value of reduced use.Full story -
ASAM: HALT Fentanyl Act Makes Fentanyl-Related Substances Schedule I. Again.
Full story -
The ASAM Weekly for March 11th, 2025
The association between buprenorphine doses above 16 milligrams and treatment retentionFull story -
TNSAM Supports Expanded Access to MOUD in Correctional Facilities
Full story -
AZSAM Supports Higher Payment Rates for Take-Home Methadone Doses
Full story -
New Guideline on Benzodiazepine Tapering
Mar 3, 2025, 12:11 by Emily Brunner, MD, DFASAM, Chwen-Yuen A. Chen, MD, FACP, FASAM, Chinyere Ogbonna, MD, MPH, Tricia Wright, MD, MS, FACOG, DFASAMThis guideline was developed to help clinicians determine when the risks of continued BZD prescribing outweigh the benefits for a given patient and how to safely taper the medication when indicated. Existing guidelines generally recommend limiting duration of BZD use to 2-4 weeks (except for limited conditions such as severe treatment-resistant generalized anxiety disorder, complex seizure disorders, spasticity, and sleep disorders involving abnormal movements). However, long-term BZD prescribing remains prevalent.Full story -
ASAM Submits Comments Supporting Final Rule on Telemedicine Initiation of Buprenorphine Treatment for OUD
Full story -
ASAM Testifies at Congressional Hearing in Support of Expanding Addiction Treatment to End the Opioid Crisis
Full story -
The ASAM Weekly for March 4th, 2025
Guest Editorial: New Clinical Practice Guideline - Benzodiazepine TaperingFull story -
The ASAM Weekly for February 18th, 2025
Cannabis Use Disorder Emergency Department Visits and Hospitalizations and 5-Year MortalityFull story -
COSAM Opposes Increasing Criminal Penalties for Possession of Synthetic Opioids
Full story -
The ASAM Weekly for February 11th, 2025
Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive DisordersFull story -
ASAM Endorses Medicare Patient Access and Practice Stabilization Act
Full story -
The ASAM Weekly for February 5th, 2025
Outpatient Low-Dose Initiation of Buprenorphine for People Using FentanylFull story -
DEA Publishes New Telemedicine Rules
Full story -
ASAM Calls for HALT Fentanyl Act Amendments to Encourage Demand-Side Action
Full story -
COSAM Supports Legislation Enhancing Parity Requirements for SUD Treatment
Full story -
ASAM Joins Coalition Letter Highlighting Tobacco Related Concerns in Appropriations Bills
Full story